Nanobiotix (NANO) Price & Analysis

Q: What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €2.62 and its highest was €25.50 in the past 12 months.

Q: What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €832.03M.

Q: When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Apr 28, 2026 which is in 136 days.

Q: Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

Q: What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is <0.01.

Q: How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 47,943,150 shares outstanding.

Q: Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

Compare

25 Followers

NANO Stock Chart & Stats

€19.90

<€0.01(0.14%)

At close: Jan 09 4:00 PM EST

€19.90

<€0.01(0.14%)

Day’s Range― - ―

52-Week Range€2.62 - €25.50

Previous CloseN/A

Volume30.64K

Average Volume (3M)654.19K

Market Cap

€832.03M

Enterprise Value€218.02M

Total Cash (Recent Filing)€28.82M

Total Debt (Recent Filing)€51.24M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Apr 28, 2026

EPS Estimate

<0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding47,943,150

10 Day Avg. Volume711,483

30 Day Avg. Volume654,186

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-2.17

Price to Sales (P/S)-12.30

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€23.00

Price Target Upside15.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FinancingThe company has secured a non-dilutive financing arrangement with HealthCare Royalty for up to $71M, extending their cash runway into early 2028.

Market ExpansionJNJ recently initiated a new Phase 1b study to evaluate JNJ-1900 in combination with chemotherapy, suggesting growing interest to extend the market opportunity of the drug.

Research And DevelopmentNanobiotix has transferred the sponsorship of the Phase 3 NANORAY-312 study to J&J, which is expected to lead to reduced operational expenses.

Bears Say

Nanobiotix News

Strategic Financial and Operational Advancements Propel Nanobiotix to a Buy Rating

Nanobiotix, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C....

17d ago

NBTX

Nanobiotix price target raised to EUR 23 from EUR 20 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 23 from EUR 20 and keeps...

1M ago

NBTX

Nanobiotix’s Strategic Financing and Clinical Expansion Signal Strong Buy Opportunity

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix, boosting the price target to €23.00....

1M ago

NBTX

Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M

Nanobiotix (NBTX) announced that it has entered into a royalty-based financing agreement with HealthCare Royalty, providing up to...

1M ago

NBTX

Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer

Nanobiotix (NBTX) announced updates to the JNJ-1900 clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship,...

2M ago

JNJ

NBTX

Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 20 from EUR 13 and keeps...

2M ago

NBTX

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

Nanobiotix (NBTX) announced first data from cohorts 1 and 2 of the dose escalation part of a Phase...

2M ago

JNJ

NBTX

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 13 from EUR 10 and keeps...

3M ago

NBTX

Nanobiotix price target raised to $14 from $9 at Leerink

Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $14 from $9 and keeps...

3M ago

NBTX

Nanobiotix announces new results from JNJ-1900 study

Nanobiotix (NBTX) announced new results focused on patients with primary cutaneous melanoma from the ongoing Phase 1 Study...

3M ago

JNJ

NBTX

Nanobiotix SA – ADR trading resumes

09:35 EDT Nanobiotix (NBTX) SA – ADR trading resumes Published first on TheFly – the ultimate source for...

5M ago

NBTX

Nanobiotix SA – ADR trading halted, volatility trading pause

09:30 EDT Nanobiotix (NBTX) SA – ADR trading halted, volatility trading pause Published first on TheFly – the...

5M ago

NBTX

Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report), retaining the...

7M ago

NBTX

Nanobiotix’s Strategic Advancements and Financial Strength Bolster Buy Rating

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Nanobiotix (NBTX – Research Report) yesterday and set...

7M ago

NBTX

NANO FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €2.62 and its highest was €25.50 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €832.03M.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Apr 28, 2026 which is in 136 days.

How were Nanobiotix SA’s earnings last quarter?

Currently, no data Available

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is <0.01.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 47,943,150 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

Company Description

Nanobiotix SA

Nanobiotix (NANO) is a clinical-stage biotechnology company focused on developing innovative cancer therapies using its proprietary nanomedicine platform. The company operates primarily in the oncology sector, where it aims to enhance the effectiveness of radiotherapy and improve patient outcomes through its core product, NBTXR3, which is designed to boost the efficacy of radiation treatment in various solid tumors. Nanobiotix is dedicated to advancing its pipeline of products and expanding its applications in cancer treatment.

Nanobiotix (NANO) Earnings & Revenues

Historic Earnings Reports

NANO Stock 12 Month Forecast

Average Price Target

€23.00

▲(15.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","26":"€26","7.25":"€7.25","13.5":"€13.5","19.75":"€19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,18.446153846153845,18.99230769230769,19.538461538461537,20.084615384615383,20.63076923076923,21.176923076923075,21.723076923076924,22.269230769230766,22.815384615384616,23.36153846153846,23.907692307692308,24.453846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,18.29230769230769,18.684615384615384,19.076923076923077,19.46923076923077,19.861538461538462,20.253846153846155,20.646153846153844,21.038461538461537,21.43076923076923,21.823076923076922,22.215384615384615,22.607692307692307,{"y":23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,18.138461538461538,18.376923076923077,18.615384615384613,18.853846153846153,19.092307692307692,19.33076923076923,19.569230769230767,19.807692307692307,20.046153846153846,20.284615384615385,20.52307692307692,20.76153846153846,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.445,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.968,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.812,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.464,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.244,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.975,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >